When the eye’s protective surface won’t heal on its own, persistent corneal epithelial defects challenge both patients and doctors with pain, vision problems, and the risk of serious complications. Understanding how to treat these stubborn wounds—from proven methods to promising new therapies—can make the difference between recovery and lasting damage.

How Treatment Aims to Restore the Cornea’s Protective Shield

The cornea’s outer layer, called the corneal epithelium, serves as the eye’s first line of defense. It creates a smooth surface for clear vision and acts as a barrier against infections and injury. When this layer is damaged, most scratches or abrasions heal quickly within a week. However, some injuries refuse to heal even after two weeks of standard care, earning the name persistent epithelial defects or PEDs.^[1]

Treatment for persistent corneal epithelial defects focuses on creating the right conditions for the eye to complete its natural healing process. The goals include protecting the exposed corneal surface, reducing inflammation that interferes with healing, preventing infection while the eye is vulnerable, and ultimately helping new epithelial cells cover the defect completely. Success depends on identifying what’s blocking normal healing—whether it’s an underlying disease, medication side effects, or structural problems with the cornea itself.^[2]

The approach to treatment must be individualized based on the patient’s specific situation. Some defects result from poor cell adhesion, where new epithelial cells can’t stick properly to the underlying tissue. Others stem from insufficient stem cells at the edge of the cornea, which are needed to generate new epithelial cells. Inflammation, nerve damage to the cornea, repeated surface trauma, or inherited conditions can all interfere with healing in different ways. Understanding the root cause guides doctors toward the most effective treatment strategy.^[1]

Timing matters critically in managing these defects. The longer a defect remains open, the more time it takes to heal, and the greater the risk of complications like infection, scarring, abnormal blood vessel growth into the cornea, or even corneal melting and perforation. Early and aggressive intervention improves outcomes, which is why doctors recommend treating persistent epithelial defects within seven to ten days to avoid secondary problems.^[2]

Standard Medical and Surgical Treatments

The foundation of treatment involves providing mechanical protection to the corneal surface while it attempts to heal. Artificial tears and lubricating eye ointments serve as the first line of defense. These products keep the surface moist and reduce friction during blinking, which can disrupt the fragile new epithelial cells trying to cover the defect. Preservative-free formulations are preferred because preservatives, especially benzalkonium chloride, can be toxic to the already-compromised corneal surface and actually delay healing.^[9]

When lubrication alone isn’t sufficient, doctors often place a bandage contact lens over the cornea. This soft, therapeutic lens acts as a protective shield, preventing the eyelid from rubbing against the defect during blinking and creating a more stable environment for healing. The lens stays in place continuously, sometimes for days or weeks. However, wearing a bandage contact lens carries its own risks—it can trap bacteria against the corneal surface, potentially leading to infection. For this reason, patients using bandage contact lenses typically receive antibiotic eye drops as a preventive measure.^[9]

Antibiotic protection is crucial during the healing period because the exposed corneal tissue is vulnerable to bacterial invasion. Fluoroquinolone antibiotics like moxifloxacin or ciprofloxacin are commonly prescribed as eye drops. These broad-spectrum antibiotics protect against many types of bacteria that could cause serious corneal infections. However, some antibiotic formulations should be avoided—besifloxacin contains a special delivery system that can block drainage pathways in the eye and cause additional corneal swelling, making it inappropriate for use with epithelial defects.^[6]

Controlling inflammation forms another pillar of standard treatment. Topical corticosteroids, or steroid eye drops, can reduce the inflammatory response that sometimes perpetuates the cycle of poor healing. However, steroids must be used carefully because they can increase infection risk and, when used improperly, may actually delay healing. Doctors typically use steroids only when the inflammatory component is significant and always in combination with antibiotics to protect against infection. The goal is to use steroids cautiously—just enough to control harmful inflammation without suppressing the immune system’s beneficial healing responses.^[15]

An oral antibiotic called doxycycline plays a special role in treating persistent epithelial defects, particularly when there’s significant involvement of the deeper corneal layers. Doxycycline belongs to the tetracycline family but is used at low doses (typically 50 milligrams twice daily) not primarily for its antibiotic effects but for its anti-inflammatory properties. It inhibits enzymes called matrix metalloproteinases that can break down corneal tissue and prevent proper healing. By blocking these destructive enzymes, doxycycline helps stabilize the corneal structure and allows epithelial cells to form proper attachments. At these low doses, doxycycline avoids the stomach upset and sun sensitivity that occur with higher antibiotic doses.^[10]

Some patients benefit from vitamin C supplementation (ascorbic acid), which supports the formation of collagen—a key structural protein in the cornea. When the corneal structure is damaged, adequate vitamin C helps the body rebuild proper tissue architecture that new epithelial cells can adhere to properly.^[15]

Addressing underlying conditions is essential for successful treatment. Patients with severe dry eye disease need aggressive management with artificial tears, anti-inflammatory medications, and sometimes procedures to block tear drainage channels to preserve moisture. Those with eyelid problems that prevent complete eye closure may need eyelid surgery or temporary taping of the eyelids during sleep. Diabetic patients require careful blood sugar control because elevated glucose levels interfere with healing processes throughout the body, including the cornea.^[4]

When these medical treatments prove insufficient, surgical options become necessary. Amniotic membrane transplantation involves placing a thin layer of tissue taken from the innermost layer of the placenta onto the corneal surface. This biological bandage provides growth factors and proteins that promote healing, reduces inflammation, and creates a scaffold for new epithelial cells to grow across. The amniotic membrane eventually dissolves as the cornea heals beneath it. Studies show that this approach can successfully heal defects that haven’t responded to conventional medical management.^[6]

Tarsorrhaphy represents another surgical approach, involving partial or complete temporary closure of the eyelids. By sewing the upper and lower eyelids together, the surgeon eliminates blinking—the mechanical force that can disrupt healing—and creates a moist, protected environment for the corneal surface. This procedure is typically reserved for severe, recalcitrant cases because it temporarily interferes with vision. Once healing is complete, the sutures are removed and the eyelids separate again.^[9]

For defects caused by poor adhesion between epithelial cells and the underlying basement membrane, doctors may perform superficial keratectomy or anterior stromal puncture. Superficial keratectomy involves carefully removing the loose, poorly adherent epithelium and sometimes the abnormal basement membrane to allow fresh, healthy tissue to regenerate. Anterior stromal puncture uses a fine needle to create tiny puncture wounds in a specific pattern on the corneal surface. These controlled micro-injuries stimulate healing responses and create small areas of scarring that help new epithelial cells anchor more firmly.^[10]

Innovative Therapies Being Tested in Clinical Trials

Beyond standard treatments, researchers are investigating promising new approaches to heal persistent epithelial defects more effectively. Clinical trials test these experimental therapies to determine their safety and whether they actually help patients heal faster or more completely than existing treatments. These studies occur in phases: Phase I trials focus primarily on safety in small groups of people, Phase II trials begin examining whether the treatment works as intended in larger groups, and Phase III trials compare the new treatment directly against standard care in even larger patient populations.^[8]

One exciting area of investigation involves growth factors—naturally occurring proteins that signal cells to grow and heal. Several growth factor therapies are in various stages of clinical testing. Epidermal growth factor (EGF) stimulates epithelial cell proliferation and migration, essentially telling cells to multiply faster and move across the defect more quickly. Eye drops containing EGF have shown promise in early clinical trials for healing persistent defects.^[2]

Nerve growth factor (NGF) addresses a specific type of persistent defect called neurotrophic keratopathy, where damage to corneal nerves impairs healing. The cornea is one of the most densely innervated tissues in the body, and these nerves don’t just sense pain—they also release substances essential for maintaining healthy epithelium. When nerve function is compromised by conditions like diabetes, herpes infection, or certain neurological disorders, the epithelium can’t heal properly. NGF eye drops aim to restore the nerve-related signals needed for normal healing. Clinical trials have demonstrated that NGF can successfully heal neurotrophic corneal defects that failed conventional treatment, leading to regulatory approval in some countries.^[8]

Thymosin beta-4 represents another growth factor under investigation. This small protein naturally present in tissues promotes cell migration and reduces inflammation. In laboratory studies and early clinical testing, thymosin beta-4 has shown ability to accelerate corneal epithelial healing and may work through multiple mechanisms—not only promoting cell movement but also moderating the inflammatory response that can interfere with healing.^[2]

Insulin-like growth factor-1 (IGF-1) plays important roles in tissue growth and repair throughout the body. Researchers have tested eye drop formulations containing IGF-1 for treating persistent epithelial defects, particularly in patients with diabetes, where insulin signaling is already disrupted. Early results suggest potential benefits, though larger studies are needed to confirm effectiveness.^[2]

Another innovative approach involves autologous serum eye drops—eye drops made from the patient’s own blood. Blood serum naturally contains growth factors, vitamins, and other substances that support corneal health. To create these personalized eye drops, a sample of the patient’s blood is drawn and processed to separate the serum, which is then diluted to appropriate concentration and provided in sterile dropper bottles. Because the drops come from the patient’s own blood, there’s no risk of immune rejection. Multiple studies have shown that autologous serum can effectively heal persistent epithelial defects, likely through the combination of multiple beneficial factors working together. This treatment is available in some specialized centers, though it’s not yet widely accessible.^[2]

Fibronectin is a protein component of the extracellular matrix—the structural framework that cells attach to and move across. Eye drops containing fibronectin provide a coating that helps epithelial cells migrate more effectively across the defect. Clinical trials have examined whether fibronectin drops can accelerate healing of persistent defects by improving the substrate that cells travel across.^[2]

For defects caused by insufficient limbal stem cells—the specialized cells at the corneal border that generate new epithelium—researchers are investigating stem cell therapies. One approach involves cultivating the patient’s own limbal stem cells in the laboratory and then transplanting them back to the affected eye. Another technique uses stem cells from a healthy donor eye. These limbal stem cell transplantation procedures aim to restore the eye’s natural capacity to regenerate epithelium. Clinical trials are evaluating the long-term success rates and optimal techniques for these transplantation approaches.^[8]

Advanced surgical techniques under investigation include various forms of tissue engineering and regenerative medicine approaches. Some research teams are developing artificial corneal constructs—laboratory-grown tissues that can be transplanted to replace damaged corneal areas. Others are testing combinations of growth factors embedded in special delivery systems that release the therapeutic substances gradually over time, potentially providing more sustained benefit than simple eye drops.^[8]

A specific treatment approach studied after cataract surgery involves combining tobramycin and dexamethasone ointment with intense pulsed light therapy and meibomian gland treatment. This comprehensive strategy addresses multiple factors: the antibiotic-steroid ointment provides medication while acting as a protective barrier, and the additional therapies target problems with the oil-producing glands in the eyelids that contribute to tear film instability. A study from China examining 26 patients with persistent epithelial dysfunction after cataract surgery found that this combined approach led to healing in most patients, with those treated recovering good vision and experiencing no significant side effects.^[6]

Researchers continue to explore the molecular mechanisms underlying epithelial healing, identifying new potential therapeutic targets. Understanding which signaling pathways become disrupted in persistent defects may lead to development of drugs that specifically address those disruptions. The mechanism of action for many experimental therapies involves affecting cellular processes at the molecular level—promoting cell survival, encouraging cell movement, supporting cell adhesion to underlying structures, or modulating inflammatory responses that interfere with healing.^[8]

Most Common Treatment Methods

• Mechanical Protection and Lubrication
  • Preservative-free artificial tears applied frequently throughout the day to maintain corneal moisture
  • Lubricating ointments, especially at bedtime, to prevent drying during sleep
  • Bandage contact lenses that shield the healing surface from mechanical trauma during blinking
• Antimicrobial Therapy
  • Topical fluoroquinolone antibiotics such as moxifloxacin or ciprofloxacin to prevent bacterial infection while the epithelium is disrupted
  • Oral doxycycline at low doses to inhibit tissue-degrading enzymes and reduce inflammation
• Anti-inflammatory Treatment
  • Topical corticosteroid eye drops used cautiously to control inflammation that perpetuates the defect
  • Anti-inflammatory properties of oral doxycycline providing systemic modulation of inflammatory responses
• Growth Factor Therapies
  • Nerve growth factor eye drops for neurotrophic defects where corneal nerve damage impairs healing
  • Autologous serum eye drops containing the patient’s own growth factors and healing proteins
  • Experimental formulations of epidermal growth factor, thymosin beta-4, or insulin-like growth factor being tested in clinical trials
• Surgical Interventions
  • Amniotic membrane transplantation placing biological tissue over the defect to promote healing
  • Tarsorrhaphy—temporary partial or complete eyelid closure to protect the corneal surface
  • Superficial keratectomy to remove abnormal basement membrane and allow fresh tissue regeneration
  • Anterior stromal puncture creating controlled micro-injuries that stimulate healing responses
  • Limbal stem cell transplantation for defects caused by stem cell deficiency
• Supportive Treatments
  • Vitamin C supplementation to support collagen formation and corneal structural repair
  • Management of underlying conditions like dry eye disease, diabetes, or eyelid abnormalities
  • Elimination or reduction of medications that impair healing, including certain glaucoma drops and preserved topical agents
• Experimental Approaches in Clinical Trials
  • Fibronectin eye drops to improve the substrate for epithelial cell migration
  • Tissue-engineered corneal constructs designed in laboratories
  • Novel drug delivery systems providing sustained release of therapeutic agents
  • Combined therapies targeting multiple healing pathways simultaneously